Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
House deadlocks on pilot to require state health plan cover GLP-1 weight-loss drugs; vote ties 50-50
Summary
Lawmakers split evenly on a two‑year pilot to require the state employee health plan to cover certain GLP-1 drugs for class‑3 obesity and polycystic ovary syndrome; the bill failed on second reading after a 50–50 tie, following extended debate over costs, side effects and utilization estimates.
Representative Rosenzweig sponsored House Bill 783, which would require the state employee health plan to cover medically necessary glucagon‑like peptide‑1 (GLP‑1) receptor agonists for people with class‑3 obesity (body mass index of 40 or higher) and for polycystic ovary syndrome when medically necessary.
Rosenzweig said the bill is a narrowly targeted, two‑year pilot limited to state employees and noted that 13 other states have adopted similar mandates for certain conditions. “This bill addresses the time period between being dangerous prediabetic and becoming fully diabetic by requiring that insurers cover the cost of the drugs when prescribed by…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
